CMPX

$0.00

(

+0.00%

)
Quote details

stock

Compass Therapeutics Inc.

NASDAQ | CMPX

4.99

USD

+$0.00

(

+0.00%

)

At Close (As of Nov 18, 2025)

$869.75M

Market Cap

-

P/E Ratio

-0.45

EPS

$5.05

52 Week High

$1.33

52 Week Low

HEALTHCARE

Sector

CMPX Chart

Recent Chart
Price Action

CMPX Technicals

Tags:

CMPX Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $850K
Total Revenue $850K
Cost Of Revenue -
Costof Goods And Services Sold -
Operating Income -$57M
Selling General And Administrative $15M
Research And Development $42M
Operating Expenses $57M
Investment Income Net -
Net Interest Income $7.3M
Interest Income $7.3M
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $1.8M
Income Before Tax -$49M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$49M
Comprehensive Income Net Of Tax -
Ebit -$57M
Ebitda -$55M
Net Income -$49M

Revenue & Profitability

Earnings Performance

CMPX Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $140M
Total Current Assets $133M
Cash And Cash Equivalents At Carrying Value $43M
Cash And Short Term Investments $43M
Inventory -
Current Net Receivables -
Total Non Current Assets $7.7M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments -
Short Term Investments $83M
Other Current Assets $6M
Other Non Current Assets -
Total Liabilities $15M
Total Current Liabilities $8.9M
Current Accounts Payable $2.2M
Deferred Revenue -
Current Debt -
Short Term Debt $338K
Total Non Current Liabilities $6.3M
Capital Lease Obligations $6.6M
Long Term Debt -
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total $6.6M
Other Current Liabilities $6.3M
Other Non Current Liabilities $1K
Total Shareholder Equity $125M
Treasury Stock -
Retained Earnings -$365M
Common Stock $13K
Common Stock Shares Outstanding $137M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$45M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $1.8M
Capital Expenditures $44K
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment $47M
Cashflow From Financing $17M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$49M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit $850K
Total Revenue $850K
Cost Of Revenue -
Costof Goods And Services Sold -
Operating Income -$57M
Selling General And Administrative $15M
Research And Development $42M
Operating Expenses $57M
Investment Income Net -
Net Interest Income $7.3M
Interest Income $7.3M
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $1.8M
Income Before Tax -$49M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$49M
Comprehensive Income Net Of Tax -
Ebit -$57M
Ebitda -$55M
Net Income -$49M

CMPX News

CMPX Profile

Compass Therapeutics Inc. Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in Boston, dedicated to developing innovative antibody-based therapies that target cancer and other severe diseases. Leveraging a state-of-the-art technology platform, the firm is advancing its proprietary drug candidates through rigorous clinical trials, aiming to deliver highly targeted treatments that enhance patient outcomes. With a robust pipeline focused on transforming the oncology landscape, Compass presents an enticing opportunity for institutional investors seeking to invest in groundbreaking advancements in cancer therapeutics.

LPTX
+368.57%
$2.05
CANF
+33.67%
$0.48
ASBP
+11.06%
$0.10
WTO
-13.33%
$0.02
LOBO
+31.12%
$0.51
PLUG
-7.12%
$2.08
NVDA
-2.94%
$181.10
CHR
-4.85%
$0.04
VHAI
-25.00%
$0.00
AXDX
-61.36%
$0.03
CMND
-2.27%
$0.27
OLMA
+143.07%
$20.71
DFLI
-1.27%
$0.80
ADAP
-15.14%
$0.05
GRAB
-1.47%
$5.33
RMBL
+60.50%
$3.21
ASST
+6.25%
$1.10
LNW
-3.71%
$86.22
ADD
-25.47%
$0.05
WBD
-1.25%
$22.74
SRM
+53.27%
$10.30
SOFI
-1.59%
$26.60
ONDS
+7.99%
$6.75
QUBT
+2.08%
$11.74
QBTS
-3.30%
$22.83
WLGS
-5.57%
$0.04
TSLA
-2.72%
$397.77
NIO
-2.96%
$5.90
MTSR
-0.35%
$70.50
TWOH
+4.16%
$0.00
KXIN
+6.97%
$0.30
CAN
+16.06%
$0.99
ONFO
+12.12%
$0.95
AMZN
-2.94%
$226.01
CRCL
-6.47%
$76.59
INTC
-1.52%
$34.18
AFMD
-34.94%
$0.18
RIOT
-0.50%
$13.88
BURU
-5.14%
$0.20
YMM
-11.93%
$10.85
MARA
+2.69%
$11.81
CIFR
+2.06%
$14.64
GPUS
-1.42%
$0.23
PFE
+0.57%
$25.22
KDLY
-9.91%
$0.55
RUBI
-0.69%
$0.17
GRYP
-10.38%
$1.38
GLMD
+7.61%
$1.13
MODV
-25.22%
$0.43
AGNC
-0.49%
$10.10
BITF
+0.28%
$2.67
F
+0.92%
$12.99
BMNR
+3.36%
$31.99
AMD
-5.00%
$228.48
SNAP
+0.97%
$8.26
UBER
+0.53%
$92.11
AUR
-7.26%
$3.83
BMNU
+11.86%
$8.77
PLTR
-1.72%
$168.29
APLT
+6.26%
$0.30
CWAN
+3.74%
$19.97
MU
-4.64%
$230.72
IONZ
-6.15%
$4.73
DVLT
-6.16%
$1.75
VINE
-9.13%
$0.37
AVGO
+0.05%
$342.65
CGTL
+20.70%
$0.80
SAND
-6.04%
$12.12
MRK
-0.06%
$92.86
TLRY
-1.29%
$1.01
IREN
+2.17%
$48.44
FIG
-2.98%
$37.38
WULF
+6.29%
$11.74
SHOT
-74.37%
$0.39
GOOGL
-1.49%
$280.75
ETHD
-7.03%
$5.28
ZAPP
-46.30%
$0.15
ETHE
-4.31%
$24.64
PLTD
+0.74%
$7.01
SOUN
-1.94%
$11.20
BYND
-0.48%
$1.03
RGTI
+0.72%
$24.87
ACHR
-0.99%
$7.34
ETH
-4.36%
$28.29
NOK
-1.02%
$6.59
RIG
+0.12%
$4.08
SMCI
+1.27%
$34.53
KVUE
+0.98%
$16.40
AAPL
+0.23%
$268.10
CRWV
-3.25%
$72.88
DNN
-0.83%
$2.37
HIMS
-0.47%
$35.40
CLSK
+0.65%
$10.68
MSFT
-3.43%
$490.08
PDD
-6.57%
$120.56
QCOM
-4.15%
$166.75
BAC
+0.80%
$51.89
HOOD
-2.11%
$113.51
NFLX
+1.16%
$111.58
DJT
-1.98%
$10.85
LPTX
+368.57%
$2.05
CANF
+33.67%
$0.48
ASBP
+11.06%
$0.10
WTO
-13.33%
$0.02
LOBO
+31.12%
$0.51
PLUG
-7.12%
$2.08
NVDA
-2.94%
$181.10
CHR
-4.85%
$0.04
VHAI
-25.00%
$0.00
AXDX
-61.36%
$0.03
CMND
-2.27%
$0.27
OLMA
+143.07%
$20.71
DFLI
-1.27%
$0.80
ADAP
-15.14%
$0.05
GRAB
-1.47%
$5.33
RMBL
+60.50%
$3.21
ASST
+6.25%
$1.10
LNW
-3.71%
$86.22
ADD
-25.47%
$0.05
WBD
-1.25%
$22.74
SRM
+53.27%
$10.30
SOFI
-1.59%
$26.60
ONDS
+7.99%
$6.75
QUBT
+2.08%
$11.74
QBTS
-3.30%
$22.83
WLGS
-5.57%
$0.04
TSLA
-2.72%
$397.77
NIO
-2.96%
$5.90
MTSR
-0.35%
$70.50
TWOH
+4.16%
$0.00
KXIN
+6.97%
$0.30
CAN
+16.06%
$0.99
ONFO
+12.12%
$0.95
AMZN
-2.94%
$226.01
CRCL
-6.47%
$76.59
INTC
-1.52%
$34.18
AFMD
-34.94%
$0.18
RIOT
-0.50%
$13.88
BURU
-5.14%
$0.20
YMM
-11.93%
$10.85
MARA
+2.69%
$11.81
CIFR
+2.06%
$14.64
GPUS
-1.42%
$0.23
PFE
+0.57%
$25.22
KDLY
-9.91%
$0.55
RUBI
-0.69%
$0.17
GRYP
-10.38%
$1.38
GLMD
+7.61%
$1.13
MODV
-25.22%
$0.43
AGNC
-0.49%
$10.10
BITF
+0.28%
$2.67
F
+0.92%
$12.99
BMNR
+3.36%
$31.99
AMD
-5.00%
$228.48
SNAP
+0.97%
$8.26
UBER
+0.53%
$92.11
AUR
-7.26%
$3.83
BMNU
+11.86%
$8.77
PLTR
-1.72%
$168.29
APLT
+6.26%
$0.30
CWAN
+3.74%
$19.97
MU
-4.64%
$230.72
IONZ
-6.15%
$4.73
DVLT
-6.16%
$1.75
VINE
-9.13%
$0.37
AVGO
+0.05%
$342.65
CGTL
+20.70%
$0.80
SAND
-6.04%
$12.12
MRK
-0.06%
$92.86
TLRY
-1.29%
$1.01
IREN
+2.17%
$48.44
FIG
-2.98%
$37.38
WULF
+6.29%
$11.74
SHOT
-74.37%
$0.39
GOOGL
-1.49%
$280.75
ETHD
-7.03%
$5.28
ZAPP
-46.30%
$0.15
ETHE
-4.31%
$24.64
PLTD
+0.74%
$7.01
SOUN
-1.94%
$11.20
BYND
-0.48%
$1.03
RGTI
+0.72%
$24.87
ACHR
-0.99%
$7.34
ETH
-4.36%
$28.29
NOK
-1.02%
$6.59
RIG
+0.12%
$4.08
SMCI
+1.27%
$34.53
KVUE
+0.98%
$16.40
AAPL
+0.23%
$268.10
CRWV
-3.25%
$72.88
DNN
-0.83%
$2.37
HIMS
-0.47%
$35.40
CLSK
+0.65%
$10.68
MSFT
-3.43%
$490.08
PDD
-6.57%
$120.56
QCOM
-4.15%
$166.75
BAC
+0.80%
$51.89
HOOD
-2.11%
$113.51
NFLX
+1.16%
$111.58
DJT
-1.98%
$10.85

Charts powered by TradingView


Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.